The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
Open accessAbstract
BACKGROUND: Remdesivir improves clinical outcomes in patients hospitalized with moderate-to-severe coronavirus disease 2019 (Covid-19). Whether the use of remdesivir in symptomatic, nonhospitalized patients with Covid-19 who are at high risk for disease progression prevents hospitalization is uncertain. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving nonhospitalized patients with Covid-19 who had symptom onset within the previous 7 days and who had at least one risk factor for disease progression (age ≥60 years, obesity, or certain coexisting medical conditions). Patients were randomly assigned to receive intravenous remdesivir (200 mg on day 1 and 100 mg on days 2 and 3) or placebo. The primary efficacy end point was a composite of Covid-19-related hospitalization or death from any cause by day 28. The primary safety end point was any adverse event. A secondary end point was a composite of a Covid-19-related medically attended visit or death from any cause by day 28. RESULTS: A total of 562 patients who underwent randomization and received at least one dose of remdesivir or placebo were included in the analyses: 279 patients in the remdesivir group and 283 in the placebo group. The mean age was 50 years, 47.9% of the patients were women, and 41.8% were Hispanic or Latinx. The most common coexisting conditions were diabetes mellitus (61.6%), obesity (55.2%), and hypertension (47.7%). Covid-19-related hospitalization or death from any cause occurred in 2 patients (0.7%) in the remdesivir group and in 15 (5.3%) in the placebo group (hazard ratio, 0.13; 95% confidence interval [CI], 0.03 to 0.59; P = 0.008). A total of 4 of 246 patients (1.6%) in the remdesivir group and 21 of 252 (8.3%) in the placebo group had a Covid-19-related medically attended visit by day 28 (hazard ratio, 0.19; 95% CI, 0.07 to 0.56). No patients had died by day 28. Adverse events occurred in 42.3% of the patients in the remdesivir group and in 46.3% of those in the placebo group. CONCLUSIONS: Among nonhospitalized patients who were at high risk for Covid-19 progression, a 3-day course of remdesivir had an acceptable safety profile and resulted in an 87% lower risk of hospitalization or death than placebo. (Funded by Gilead Sciences; PINETREE ClinicalTrials.gov number, NCT04501952; EudraCT number, 2020-003510-12.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
Remdesivir for the Treatment of Covid-19 — Final Report
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007764 · Cited by 7,267
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection
The INSIGHT START Study Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506816 · Cited by 2,798
Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results
WHO Solidarity Trial Consortium (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2023184 · Cited by 2,745
COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal
Siddiqi, H. K., & Mehra, M. R. (2020) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2020.03.012 · Cited by 1,701
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
Weinreich, D. M., Sivapalasingam, S., Norton, T., Ali, S., Gao, H., Bhore, R., Musser, B. J., Soo, Y., Rofail, D., Im, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035002 · Cited by 1,642
Self-citationA Randomized, Controlled Trial of Ebola Virus Disease Therapeutics
Mulangu, S., Dodd, L. E., Davey, R. T., Tshiani Mbaya, O., Proschan, M., Mukadi, D., Lusakibanza Manzo, M., Nzolo, D., Tshomba Oloma, A., Ibanda, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910993 · Cited by 1,605
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
Sheahan, T. P., Sims, A. C., Graham, R. L., Menachery, V. D., Gralinski, L. E., Case, J. B., Leist, S. R., Pyrc, K., Feng, J. Y., Trantcheva, I., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3653 · Cited by 1,571
Coronavirus disease 2019 case surveillance—United States, January 22–May 30, 2020.
Stokes, E. K., Zambrano, L. D., Anderson, K. N., Marder, E. P., Raz, K. M., El Burai Felix, S., Tie, Y., & Fullerton, K. E. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6924e2 · Cited by 1,538
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
Goldman, J. D., Lye, D. C. B., Hui, D. S., Marks, K. M., Bruno, R., Montejano, R., Spinner, C. D., Galli, M., Ahn, M.-Y., Nahass, R. G., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2015301 · Cited by 1,362
Self-citationSpinner, C. D., Gottlieb, R. L., Criner, G. J., Arribas López, J. R., Cattelan, A. M., Soriano Viladomiu, A., Ogbuagu, O., Malhotra, P., Mullane, K. M., Castagna, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.16349 · Cited by 1,211
Self-citationEarly treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab
Gupta, A., Gonzalez-Rojas, Y., Juarez, E., Crespo Casal, M., Moya, J., Falci, D. R., Sarkis, E., Solis, J., Zheng, H., Scott, N., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107934 · Cited by 1,086
Gottlieb, R. L., Nirula, A., Chen, P., Boscia, J., Heller, B., Morris, J., Huhn, G., Cardona, J., Mocherla, B., Stosor, V., et al. (2021) · JAMA · doi:10.1001/jama.2021.0202 · Cited by 872
Self-citationPredictors of COVID‐19 severity: A literature review
Gallo Marin, B., Aghagoli, G., Lavine, K., Yang, L., Siff, E. J., Chiang, S. S., Salazar‐Mather, T. P., Dumenco, L., Savaria, M. C., Aung, S. N., et al. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2146 · Cited by 819
Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial
Nicholson, K., Aoki, F., Osterhaus, A., Trottier, S., Carewicz, O., Mercier, C., Rode, A., Kinnersley, N., & Ward, P. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02288-1 · Cited by 785
Virology, transmission, and pathogenesis of SARS-CoV-2
Cevik, M., Kuppalli, K., Kindrachuk, J., & Peiris, M. (2020) · BMJ · doi:10.1136/bmj.m3862 · Cited by 732
Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2
Williamson, B. N., Feldmann, F., Schwarz, B., Meade-White, K., Porter, D. P., Schulz, J., van Doremalen, N., Leighton, I., Yinda, C. K., Pérez-Pérez, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2423-5 · Cited by 689
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
Dougan, M., Nirula, A., Azizad, M., Mocherla, B., Gottlieb, R. L., Chen, P., Hebert, C., Perry, R., Boscia, J., Heller, B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2102685 · Cited by 663
Self-citationMuthuri, S. G., Venkatesan, S., Myles, P. R., Leonardi-Bee, J., Al Khuwaitir, T. S. A., Al Mamun, A., Anovadiya, A. P., Azziz-Baumgartner, E., Báez, C., Bassetti, M., et al. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70041-4 · Cited by 644
Ader, F., Bouscambert-Duchamp, M., Hites, M., Peiffer-Smadja, N., Poissy, J., Belhadi, D., Diallo, A., Lê, M.-P., Peytavin, G., Staub, T., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00485-0 · Cited by 325
Characterization and Treatment of SARS-CoV-2 in Nasal and Bronchial Human Airway Epithelia
Pizzorno, A., Padey, B., Julien, T., Trouillet-Assant, S., Traversier, A., Errazuriz-Cerda, E., Fouret, J., Dubois, J., Gaymard, A., Lescure, F.-X., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100059 · Cited by 252
In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains
Chen, R. E., Winkler, E. S., Case, J. B., Aziati, I. D., Bricker, T. L., Joshi, A., Darling, T. L., Ying, B., Errico, J. M., Shrihari, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03720-y · Cited by 220
Mozaffari, E., Chandak, A. N., Zhang, Z., Liang, S., Thrun, M. W., Gottlieb, R., Kuritzkes, D. R., Sax, P. E., Wohl, D. A., Casciano, R., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab875 · Cited by 124
Self-citationSchäfer, A., Martinez, D. R., Won, J. J., Moreira, F. R., Brown, A. J., Gully, K. L., Kalla, R. V., Chun, K., Pont, V. D., Babusis, D. M., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.13.460111 · Cited by 23
Cited by
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
Hammond, J., Leister-Tebbe, H., Gardner, A., Abreu, P., Bao, W., Wisemandle, W., Baniecki, M., Hendrick, V. M., Damle, B., Simón-Campos, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2118542 · Cited by 2,323
Long COVID science, research and policy
Al-Aly, Z., Davis, H., McCorkell, L., Soares, L., Wulf-Hanson, S., Iwasaki, A., & Topol, E. J. (2024) · Nature Medicine · doi:10.1038/s41591-024-03173-6 · Cited by 538
Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults
Killingley, B., Mann, A. J., Kalinova, M., Boyers, A., Goonawardane, N., Zhou, J., Lindsell, K., Hare, S. S., Brown, J., Frise, R., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01780-9 · Cited by 530
Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir
Iketani, S., Mohri, H., Culbertson, B., Hong, S. J., Duan, Y., Luck, M. I., Annavajhala, M. K., Guo, Y., Sheng, Z., Uhlemann, A.-C., et al. (2023) · Nature · doi:10.1038/s41586-022-05514-2 · Cited by 480
Vangeel, L., Chiu, W., De Jonghe, S., Maes, P., Slechten, B., Raymenants, J., André, E., Leyssen, P., Neyts, J., & Jochmans, D. (2022) · Antiviral Research · doi:10.1016/j.antiviral.2022.105252 · Cited by 433
Metadata
- Authors
- Gottlieb, R. L., Vaca, C. E., Paredes, R., Mera, J., Webb, B. J., Perez, G., Oguchi, G., Ryan, P., Nielsen, B. U., Brown, M., Hidalgo, A., Sachdeva, Y., Mittal, S., Osiyemi, O., Skarbinski, J., Juneja, K., Hyland, R. H., Osinusi, A., Chen, S., Camus, G., Abdelghany, M., Davies, S., Behenna-Renton, N., Duff, F., Marty, F. M., Katz, M. J., Ginde, A. A., Brown, S. M., Schiffer, J. T., & Hill, J. A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-01-27
- Volume
- 386
- Issue
- 4
- Pages
- 305-315
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4200206478
- Cited by
- 1,231
- References
- 25
- FWCI
- 77.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.